TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 GEOGRAPHICAL SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 PRODUCT TYPE LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 MARKET END USER COVERAGE GRID 28
2.11 SECONDARY SOURCES 29
2.12 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 33
4.1 PESTEL ANALYSIS 34
4.2 PORTERS FIVE FPRCES 35
5 INDUSTRY INSIGHTS 36
6 REGULATORY FRAMEWORK 38
6.1 REGULATIONS IN THE U.S. 38
6.2 REGULATIONS IN CANADA 39
6.3 REGULATIONS IN MEXICO 39
7 MARKET OVERVIEW 41
7.1 DRIVERS 43
7.1.1 GROWING PREVALENCE OF COLD SORE INFECTION 43
7.1.2 PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS 43
7.1.3 AVAILABILITY OF GENERIC DRUGS 44
7.1.4 RISING DISPOSABLE INCOME AND INCREASING HEALTHCARE INFRASTRUCTURE 44
7.2 RESTRAINTS 45
7.2.1 THE DEARTH OF AWARENESS ABOUT THE ONSET AND SYMPTOMS OF COLD SORE AND ITS TREATMENT 45
7.2.2 PATENT TERMINATION OF MARKETED DRUGS 45
7.3 OPPORTUNITIES 46
7.3.1 INCREASING USE OF COLD SORE PATCHES 46
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 47
3.3 INCREASING RESEARCH AND DEVELOPMENT FOR COLD SORE PATCHES 47
3.4 RISE IN THE DEMAND FOR ANTI-VIRAL DRUGS FOR COLD SORE TREATMENT 48
7.4 CHALLENGES 49
7.4.1 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR TREATING COLD SORES 49
7.4.2 RISE IN THE ADOPTION OF ALTERNATIVE HOME REMEDIES FOR COLD SORE TREATMENT 49
8 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE 51
8.1 OVERVIEW 52
8.2 MEDICATIONS 55
8.2.1 ANTIVIRAL AGENTS 55
8.2.1.1 ACYCLOVIR 56
8.2.1.2 FAMCICLOVIR 56
8.2.1.3 VALACYCLOVIR 56
8.2.1.4 OTHERS 56
8.2.2 ANALGESICS AGENTS 56
8.2.3 OTHERS 56
8.3 OINTMENTS 56
8.3.1 GENERICS 57
8.3.2 BRANDED 57
8.3.2.1 ABREVA 58
8.3.2.2 BLISTEX 58
8.3.2.3 OTHERS 58
8.4 CREAMS 58
8.5 MEDICATED LIP BALMS 58
8.6 COLD SORE PATCHES 59
8.6.1 SEMI OCCLUSIVE HYDROCOLLOID PATCH 59
8.6.2 FILM-FORMING PATCH 59
8.7 NON-MEDICATED PRODUCTS 60
9 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY ROUTE OF ADMINISTRATION 61
9.1 OVERVIEW 62
9.2 ORAL 65
9.2.1 TABLET 65
9.2.2 CAPSULE 65
9.2.3 OTHERS 65
9.3 TOPICAL 65
9.3.1 OINTMENTS 66
9.3.2 CREAMS 66
9.3.3 LIP BALM 66
9.4 OTHERS 66
10 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY TYPE 68
10.1 OVERVIEW 69
10.2 OVER THE COUNTER (OTC) DRUGS 72
10.3 PRESCRIPTION DRUGS 72
11 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY GENDER 73
11.1 OVERVIEW 74
11.2 FEMALE 77
11.3 MALE 77
12 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DRUG TYPE 78
12.1 OVERVIEW 79
12.2 GENERICS 82
12.3 BRANDED 82
13 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY END-USER 83
13.1 OVERVIEW 84
13.2 HOMECARE SETTING 87
13.3 HOSPITALS 87
13.4 SPECIALTY CLINICS 87
13.5 OTHERS 88
14 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET, BY DISTRIBUTION CHANNEL 89
14.1 OVERVIEW 90
14.2 RETAIL PHARMACY 93
14.3 HOSPITAL PHARMACY 93
14.4 ONLINE PHARMACY 94
15 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET BY COUNTRY 95
15.1 NORTH AMERICA 95
15.1.1 U.S. 101
15.1.2 CANADA 105
15.1.3 MEXICO 109
16 NORTH AMERICA COLD SORE TREATMENT (FOR HSV 1 VIRUS) MARKET: COMPANY LANDSCAPE 113
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 113
17 SWOT ANALYSIS 114
18 COMPANY PROFILES 115
18.1 GSK PLC. 115
18.1.1 COMPANY SNAPSHOT 115
18.1.2 REVENUE ANALYSIS 115
18.1.3 PRODUCT PORTFOLIO 116
18.1.4 RECENT DEVELOPMENT 116
18.2 HALEON GROUP OF COMPANIES 117
18.2.1 COMPANY SNAPSHOT 117
18.2.2 REVENUE ANALYSIS 117
18.2.3 PRODUCT PORTFOLIO 118
18.2.4 RECENT DEVELOPMENT 118
18.3 VIATRIS INC. 119
18.3.1 COMPANY SNAPSHOT 119
18.3.2 REVENUE ANALYSIS 119
18.3.3 PRODUCT PORTFOLIO 120
18.3.4 RECENT DEVELOPMENTS 120
18.4 QUANTUM HEALTH 121
18.4.1 COMPANY SNAPSHOT 121
18.4.2 PRODUCT PORTFOLIO 121
18.4.3 RECENT DEVELOPMENTS 121
18.5 TEVA PHARMACEUTICALS USA, INC. (SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 122
18.5.1 COMPANY SNAPSHOT 122
18.5.2 REVENUE ANALYSIS 122
18.5.3 PRODUCT PORTFOLIO 123
18.5.4 RECENT DEVELOPMENT 123
18.6 AMPARO MEDICAL TECHNOLOGIES 124
18.6.1 COMPANY SNAPSHOT 124
18.6.2 PRODUCT PORTFOLIO 124
18.6.3 RECENT DEVELOPMENT 124
18.7 APOTEX INC. 125
18.7.1 COMPANY SNAPSHOT 125
18.7.2 PRODUCT PORTFOLIO 125
18.7.3 RECENT DEVELOPMENTS 125
18.8 BAUSCH HEALTH COMPANIES INC. 126
18.8.1 COMPANY SNAPSHOT 126
18.8.2 REVENUE ANALYSIS 126
18.8.3 PRODUCT PORTFOLIO 127
18.8.4 RECENT DEVELOPMENT 127
18.9 BLISTEX INC. 128
18.9.1 COMPANY SNAPSHOT 128
18.9.2 PRODUCT PORTFOLIO 128
18.9.3 RECENT DEVELOPMENT 128
18.10 CARMA LABS INC. 129
18.10.1 COMPANY SNAPSHOT 129
18.10.2 PRODUCT PORTFOLIO 129
18.10.3 RECENT DEVELOPMENT 129
18.11 CHURCH & DWIGHT CO., INC. 130
18.11.1 COMPANY SNAPSHOT 130
18.11.2 REVENUE ANALYSIS 130
18.11.3 PRODUCT PORTFOLIO 131
18.11.4 RECENT DEVELOPMENT 131
18.12 HIKMA PHARMACEUTICALS PLC 132
18.12.1 COMPANY SNAPSHOT 132
18.12.2 REVENUE ANALYSIS 132
18.12.3 PRODUCT PORTFOLIO 133
18.12.4 RECENT DEVELOPMENTS 133
18.13 HRA PHARMA 134
18.13.1 COMPANY SNAPSHOT 134
18.13.2 PRODUCT PORTFOLIO 134
18.13.3 RECENT DEVELOPMENTS 134
18.14 NOVARTIS AG 135
18.14.1 COMPANY SNAPSHOT 135
18.14.2 REVENUE ANALYSIS 135
18.14.3 PRODUCT PORTFOLIO 136
18.14.4 RECENT DEVELOPMENTS 136
18.15 URGO 137
18.15.1 COMPANY SNAPSHOT 137
18.15.2 PRODUCT PORTFOLIO 137
18.15.3 RECENT DEVELOPMENTS 137
18.16 ZYDUS PHARMACEUTICALS, INC. (SUBSIDIARY OF ZYDUS GROUP) 138
18.16.1 COMPANY SNAPSHOT 138
18.16.2 REVENUE ANALYSIS 138
18.16.3 PRODUCT PORTFOLIO 139
18.16.4 RECENT DEVELOPMENT 139
19 QUESTIONNAIRE 140
20 RELATED REPORTS 144

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.